Inhibition Effect and Mechanism of Xiancidan on Lewis Lung Cancer in Mice

LI Jing; WANG Pei-pei; HUANG Song; CHEN Ling-ling; FENG Hong-rui; DU Xian-hua

doi:10.11653/syfj2013110208

您当前的位置：

首页 >

文章列表页 >

Inhibition Effect and Mechanism of Xiancidan on Lewis Lung Cancer in Mice

更新时间：2024-01-04

- Inhibition Effect and Mechanism of Xiancidan on Lewis Lung Cancer in Mice
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 19, Issue 11, Pages: 208-212(2013)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.11653/syfj2013110208
  CLC：
- Published：2013
- 稿件说明：
移动端阅览
LI Jing, WANG Pei-pei, HUANG Song, et al. Inhibition Effect and Mechanism of Xiancidan on Lewis Lung Cancer in Mice[J]. Chinese journal of experimental traditional medical formulae, 2013, 19(11): 208-212.
DOI：

LI Jing, WANG Pei-pei, HUANG Song, et al. Inhibition Effect and Mechanism of Xiancidan on Lewis Lung Cancer in Mice[J]. Chinese journal of experimental traditional medical formulae, 2013, 19(11): 208-212. DOI： 10.11653/syfj2013110208.

摘要

目的: 探讨仙慈丹对小鼠Lewis肺癌的生长抑制

免疫调节

细胞周期及凋亡的影响

并对其抗癌作用机制进行探讨。方法: 选择C57BL/6小鼠移植性Lewis肺癌为实验模型进行试验

造模5 d后

分为模型对照组、顺铂给药组、仙慈丹高、中、低剂量组、联合用药组

给药13 d

给药剂量(mg·kg-1)分别为0

2.0(ip)

0.648(ig)

0.324(ig)

0.162(ig)

0.162(ig)+2.0(ip);观察仙慈丹有效部位对小鼠肺癌的抑制、免疫调节的影响

同时采用流式细胞仪检测肿瘤组织的细胞周期、凋亡率

应用免疫蛋白印记法(Western blot法)观察仙慈丹有效部位对p53

Bcl-2表达的影响。结果: ①抑瘤率:阳性药物顺铂组、仙慈丹高、中、低各给药组、联合给药组分别为(63.02±3.21)%

(46.59±2.60)%

(42.48±2.77)%

(15.74±1.94)%

(64.56±1.62)%;②脾脏指数:仙慈丹高、中、低各给药组指数较高

与阳性药物组比较具有显著性差异(P<0.01);③荷瘤小鼠肿瘤细胞凋亡率:模型对照组、阳性药物组、仙慈丹高、中、低各给药组、联合给药组分别为0.04%

30.40%

14.80%

17.98%

16.04%

20.34%;④阳性药物组、仙慈丹高、中给药组、联合用药组的G0/G1细胞所占百分比与模型组比较具有显著性差异(P<0.01);⑤p53及Bcl-2表达量:仙慈丹高、中、低给药组及顺铂仙慈丹联合用药组表达量均降低

与模型组比较具有显著性差异(P<0.01)。结论: 仙慈丹有效部位可以抑制Lewis肺癌生长

其抗癌作用与诱导细胞凋亡

调节细胞周期有关。

Abstract

Objective: To investigate the inhibition effects of Xiancidan(XCD) on the lung-cancer cell in Lewis tumor-bearing mice and explore its mechanism. Method: C57BL/6 mice were taken as model

and divided into model group

cis-platinum group

high dose group XCD

middle dose group XCD

low dose group XCD

combination of XCD and control group 5 days later

All groups were administrated for 13 days

and the respective dosage was 0

2.0(ip)

0.648(ig)

0.324(ig)

0.162(ig)

0.162(ig)+2.0(ip).To observe the effect of XCD on inhibition of the lung cancer cell and immune regulation

AnnexinⅤ-FITC/PI method was applied to determine the apoptosis and cycle of transplanted cancer cells and Western blot method was used to observe the p53

Bcl-2 gene expression. Result: ①The inhibition rate in positive control group

high dose group

middle dose group

low dose groupof XCD

combination of XCD and control group were(63.02±3.21)%

(46.59±2.60)%

(42.48±2.77)%

(15.74±1.94)%

(64.56±1.62)%.②The pleen Index of high dose group XCD

middle dose group XCD and low dose group were significantly different from model group(P<0.01). ③The apoptosis rate of model group

control group

high dose group XCD

middle dose group XCD

low dose group XCD

the combination group of XCD and positive drug was 0.04%

30.40%

14.80%

17.98%

16.04%

20.34%

respectively.④Compared with model group

the percentage of G0/G1 cell in positive control group

high dose group XCD

middle dose group XCD and the combination groupm was significantly decreased. ⑤The p53 expression and Bcl-2 rate was significantly different from model group. Conclusion: The XCD effective parts can inhibit the growth of lewis tumor

which is related to its apoptosis-inducing and immune regulation effect.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Inhibitory Effect of Sophora alopecuroides Total Alkaloids and Two Monomer Alkaloids on PC12 Cell Activity

Efficacy and Mechanism of Shenbai Jiedu Prescription Against Proliferation of HCT116 Cells

In Vitro Antitumor Bioactivity and GC-MS Analysis of Petroleum Ether Fraction of Boehmeria nivea Root

Experimental Study of Shuang Ling Fuzheng Kangai Capsule(SLFKC) on Inhibiting Heps of Mouse

Research Review on Anti-cancer Action and Mechanism of

Related Author

GAO Li

LUO Fuxiang

ANAER Mahemuti

LUO Jingying

YAN Ming

Dong JIANG

Haibo CHENG

Weixing SHEN

Related Institution

Xinjiang Key Laboratory of Uighur Medical Prescription，Xinjiang Institute of Traditional Uighur Medicine

The First Clinical College of Nanjing University of Chinese Medicine

Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine in Prevention and Treatment of Tumor

Jiangsu Province Hospital of Chinese Medicine，Affiliated Hospital of Nanjing University of Chinese Medicine

School of Pharmacy, Liaoning University of Traditional Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰